Navigation Links
Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

~ Presentations Include 1 Oral Session and 21 Poster Sessions ~

~ Replidyne Debuts New Clostridium difficile Program ~

LOUISVILLE, Colo., Sept. 17 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it will be presenting 21 posters highlighting three major pipeline programs at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held at the McCormick Place conference center in Chicago. The posters will showcase previously unpublished data related to faropenem medoxomil (faropenem), Replidyne's Phase III clinical program for the treatment of community-acquired respiratory tract infections in adults and children; REP8839, Replidyne's Phase II topical antibiotic initially targeted for the treatment of impetigo, the most common bacterial skin infection in children; and REP3123, Replidyne's newly disclosed lead product candidate to treat Clostridium difficile (C. difficile) related diseases, a major cause of morbidity among the elderly and hospitalized patients.

"We are excited to be presenting a wealth of information on our novel anti-infective pipeline at the premier scientific conference in this field. The presentation and posters showcase the depth of our pipeline and the productivity of our research and development organization," commented Kenneth J. Collins, Replidyne President and CEO. "In particular, we will be presenting data highlighting the scientific promise of our preclinical C. difficile program."

REP3123 Presentations

Today at the All New Antimicrobial Agents session, Replidyne's Chief Scientific Officer and company co-founder, Nebojsa Janjic, Ph.D., unveiled highly-anticipated details of Replidyne's C. difficile program. The presentation introduced REP3123, highlighting key preclinical findings including its ability to inhibit growth, halt toxin production and prevent spore-formation of the Gram-positive C. difficile bacterium without inhibiting other key organisms that are essential for normal intestinal functioning.

Replidyne will present the following C. difficile posters on Thursday, September 20 at 10:00 AM, Room E253D:

-- Poster F1-2112, titled "Novel Inhibitors of Methionyl tRNA Synthestase

from Clostridium difficile: Identification and Synthesis of REP3123."

-- Poster F1-2113, titled "REP3123 is a Potent and Selective Inhibitor of

Methionyl tRNA Synthetase from Clostridium difficile."

-- Poster F1-2114, titled "Co-crystal Structure of REP3123 Bound to

Clostridium difficile Methionyl tRNA Synthetase."

-- Poster F1-2115, titled "Spectrum of Activity of REP3123 against

Aerobic Bacterial Pathogens."

-- Poster F1-2117, titled "In vitro Activity of REP3123 against

Clostridium difficile and Other Anaerobic Intestinal Bacteria."

-- Poster F1-2118, titled "REP3123: A Narrow Spectrum Antibacterial Agent

that Inhibits Growth and Prevents Sporulation in Clostridium


-- Poster F1-2119, titled "REP3123 Inhibits Toxin Production in C.


-- Poster F1-2120, titled "Efficacy of Novel MetRS Inhibitors in a C.

difficile Hamster Model."

Faropenem Presentations

Monday, September 17 at 12:00 PM, Hall D:

-- Poster E-256, titled "Comparison of the Bactericidal Activities of

Faropenem, Ertapenem, Amoxicillin, Cefixime, Cefuroxime and

Moxifloxacin against Streptococcus pneumoniae."

-- Poster E-257, titled "Comparative Ability of Faropenem to Select for

Resistant Mutants of S. pneumoniae."

-- Poster E-258, titled "Comparative Ability of Faropenem to Select for

Resistant Mutants in H. influenzae."

-- Poster C2-200, titled "Antimicrobial Resistance Patterns among

Streptococcus pneumoniae Isolated from Children in the U.S. 2005-2006

Faropenem Surveillance Study."

-- Poster D-238, titled "An Evaluation of Dried MIC Susceptibility Plate

Compared to the CLSI (M7) Reference Broth Microdilution Method with

the New Antimicrobial Agent, Faropenem."

-- Poster C2-214, titled "Comparative Affinity of Faropenem to Penicillin

Binding Proteins (PBPs) of Pneumococci with Varying Beta-Lactam


Monday, September 17 at 1:00 PM, Hall D:

-- Poster L-480, titled "A Double-Blind, Randomized, Dose Ranging Study

to Evaluate the Safety of Faropenem Medoxomil (FM) at 300 or 600 mg

BID for Seven Days in Healthy Volunteers."

-- Poster L-481, titled "A Phase II Double-Blind, Randomized Trial

Comparing Faropenem Medoxomil at 300 mg BID for Seven Days and 600 mg

BID for Five Days in Subjects with Acute Maxillary Sinusitis Diagnosed

by Antral Tap."

Tuesday, September 18 at 11:15 AM, Hall D:

-- Poster G-980, titled "Monitoring Changes in Susceptibility of Middle

Ear Fluid (MEF), Nasopharyngeal (NP) and Oropharyngeal (OP) Pathogens

to Faropenem in a Phase II Acute Otitis Media (AOM) Study."

-- Poster G-983, titled "Use of Parent-reported Outcome Measure in Acute

Otitis Media Clinical Trials."

-- Poster G-987, titled "Dose-effect of Faropenem Medoxomil (FM) in the

Treatment of Acute Otitis Media."

Wednesday, September 19 at 11:15 AM, Hall D:

-- Poster A-1435, titled "Pharmacokinetic-Pharmacodynamic (PK-PD)

Assessment of Faropenem (FAR) in a Lethal Murine-Bacillus anthracis

(BA) Inhalation Post-Exposure Prophylaxis Model."

REP8839 Presentation

Thursday, September 20 at 10:00 AM, Room E253D:

-- Poster F1-2116, titled "In vitro Activity of REP8839 against

Pasteurella species and Other Fastidious Bacteria Isolated from

Infected Animal Bites in Humans."

About Clostridium difficile

C. difficile is a Gram-positive anaerobic bacterium that causes C. difficile-associated disease (CDAD). CDAD is on the rise worldwide, both in terms of number of cases and severity of the disease. Most cases of CDAD occur in a hospital setting due to increased use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile spores. However, more recently, CDAD has been acquired in the community setting where several outbreaks with increased mortality have occurred. The emergence of an epidemic, hypervirulent C. difficile strain (BI/NAP1, 027) that produces high levels of toxins poses a real threat to public health and demands improved infection control as well as novel treatment options.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and related diseases. In preclinical studies, REP3123 has been show to inhibit growth, toxin production and spore-forming in C. difficile bacteria. Replidyne is also pursuing the development of other novel anti-infective programs based on its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
2. $30 M Aid in the pipeline by WB for bird flu in Turkey
3. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
4. Battery power from viruses in the pipeline
5. Effective Vaccine for Leishmaniasis in the Pipeline
6. Home Test Kit for AIDS in the Pipeline
7. Sensing Devices to Measure Sleep In the Pipeline
8. Blood Fluke Vaccine in the Pipeline
9. Chlamydial Vaccine for Humans in the Pipeline
10. New Treatment Option in the Pipeline for Those Suffering From Lung Cancers
11. Treatment of Endometriosis in the Pipeline
Post Your Comments:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology: